[1] LEWIS G D, LI G M, GUO J, et al. The HER2-directed antibody-drug conjugate DHES0815A in advanced and/or metastatic breast cancer: preclinical characterization and phase 1 trial results[J]. Nat Commun, 2024, 15(1): 466. doi:  10.1038/s41467-023-44533-z
[2] DE SAUVAGE M A, TORRINI C, NIEBLAS-BEDOLLA E, et al. The ERK inhibitor LY3214996 augments anti-PD-1 immunotherapy in preclinical mouse models of BRAFV600E melanoma brain metastasis[J]. Neuro Oncol, 2024, 26(5): 889-901. doi:  10.1093/neuonc/noad248
[3] XUE Y E, CHE J Y, JI X M, et al. Recent advances in biomaterial-boosted adoptive cell therapy[J]. Chem Soc Rev, 2022, 51(5): 1766-1794. doi:  10.1039/D1CS00786F
[4] FAN T, ZHANG M N, YANG J X, et al. Therapeutic cancer vaccines: advancements, challenges, and prospects[J]. Signal Transduct Target Ther, 2023, 8(1): 450. doi:  10.1038/s41392-023-01674-3
[5] TAGLIAMONTE M, CAVALLUZZO B, MAURIELLO A, et al. Molecular mimicry and cancer vaccine development[J]. Mol Cancer, 2023, 22(1): 75. doi:  10.1186/s12943-023-01776-0
[6] SAHIN U, TÜRECI Ö. Personalized vaccines for cancer immunotherapy[J]. Science, 2018, 359(6382): 1355-1360. doi:  10.1126/science.aar7112
[7] DIAO L, LIU M. Rethinking antigen source: cancer vaccines based on whole tumor cell/tissue lysate or whole tumor cell[J]. Adv Sci, 2023, 10(22): e2300121. doi:  10.1002/advs.202300121
[8] SHIREMAN J M, GONUGUNTA N, ZHAO L, et al. GM-CSF and IL-7 fusion cytokine engineered tumor vaccine generates long-term Th-17 memory cells and increases overall survival in aged syngeneic mouse models of glioblastoma[J]. Aging Cell, 2023, 22(7): e13864. doi:  10.1111/acel.13864
[9] AIKINS M E, XU C, MOON J J. Engineered nanoparticles for cancer vaccination and immunotherapy[J]. Acc Chem Res, 2020, 53(10): 2094-2105. doi:  10.1021/acs.accounts.0c00456
[10] ZHANG X, ZHANG H B, GU J M, et al. Engineered extracellular vesicles for cancer therapy[J]. Adv Mater, 2021, 33(14): e2005709. doi:  10.1002/adma.202005709
[11] KORBELIK M. Radiovaccination strategy for cancer treatment integrating photodynamic therapy-generated vaccines with radiotherapy[J]. Int J Mol Sci, 2022, 23(20): 12263. doi:  10.3390/ijms232012263
[12] GALLUZZI L, HUMEAU J, BUQUÉ A, et al. Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors[J]. Nat Rev Clin Oncol, 2020, 17(12): 725-741. doi:  10.1038/s41571-020-0413-z
[13] PETRONI G, BUQUÉ A, ZITVOGEL L, et al. Immunomodulation by targeted anticancer agents[J]. Cancer Cell, 2021, 39(3): 310-345. doi:  10.1016/j.ccell.2020.11.009
[14] RODRIGUEZ-RUIZ M E, VITALE I, HARRINGTON K J, et al. Immunological impact of cell death signaling driven by radiation on the tumor microenvironment[J]. Nat Immunol, 2020, 21(2): 120-134. doi:  10.1038/s41590-019-0561-4
[15] SEAVER K, KOURKO O, GEE K, et al. IL-27 improves prophylactic protection provided by a dead tumor cell vaccine in a mouse melanoma model[J]. Front Immunol, 2022, 13: 884827. doi:  10.3389/fimmu.2022.884827
[16] LUO L M, LV M H, ZHUANG X B, et al. Irradiation increases the immunogenicity of lung cancer cells and irradiation-based tumor cell vaccine elicits tumor-specific T cell responses in vivo[J]. Onco Targets Ther, 2019, 12: 3805-3815. doi:  10.2147/OTT.S197516
[17] HUMEAU J, SAUVAT A, CERRATO G, et al. Inhibition of transcription by dactinomycin reveals a new characteristic of immunogenic cell stress[J]. EMBO Mol Med, 2020, 12(5): e11622. doi:  10.15252/emmm.201911622
[18] AHN I E, BRANDER D M, REN Y, et al. Five-year follow-up of a phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial therapy in CLL[J]. Blood Adv, 2024, 8(4): 832-841. doi:  10.1182/bloodadvances.2023011574
[19] MONTES DE OCA R, ALAVI A S, VITALI N, et al. Belantamab mafodotin(GSK2857916)drives immunogenic cell death and immune-mediated antitumor responses in vivo[J]. Mol Cancer Ther, 2021, 20(10): 1941-1955. doi:  10.1158/1535-7163.MCT-21-0035
[20] FIELD C S, HERMANS I F, HUNN M K. Whole tumor cell vaccines for glioma immunotherapy[J]. Immunotherapy, 2016, 8(4): 387-389. doi:  10.2217/imt-2015-0022
[21] WONG K K, LI W A, MOONEY D J, et al. Advances in therapeutic cancer vaccines[J]. Adv Immunol, 2016, 130: 191-249.
[22] LUO G F, CHEN W H, ZENG X, et al. Cell primitive-based biomimetic functional materials for enhanced cancer therapy[J]. Chem Soc Rev, 2021, 50(2): 945-985. doi:  10.1039/D0CS00152J
[23] TSUJIKAWA T, CROCENZI T, DURHAM J N, et al. Evaluation of cyclophosphamide/GVAX pancreas followed by Listeria-mesothelin(CRS-207)with or without nivolumab in patients with pancreatic cancer[J]. Clin Cancer Res, 2020, 26(14): 3578-3588. doi:  10.1158/1078-0432.CCR-19-3978
[24] BERNARDES DE JESUS B, NEVES B M, FERREIRA M, et al. Strategies for cancer immunotherapy using induced pluripotency stem cells-based vaccines[J]. Cancers, 2020, 12(12): 3581. doi:  10.3390/cancers12123581
[25] GUO M, YOU C Z, DOU J. Role of transmembrane glycoprotein mucin 1(MUC1)in various types of colorectal cancer and therapies: Current research status and updates[J]. Biomed Pharmacother, 2018, 107: 1318-1325. doi:  10.1016/j.biopha.2018.08.109
[26] GUO M, LUO B, PAN M, et al. Colorectal cancer stem cell vaccine with high expression of MUC1 serves as a novel prophylactic vaccine for colorectal cancer[J]. Int Immunopharmacol, 2020, 88: 106850. doi:  10.1016/j.intimp.2020.106850
[27] AI X, WANG S, DUAN Y, et al. Emerging approaches to functionalizing cell membrane-coated nanoparticles[J]. Biochemistry, 2021, 60(13): 941-955. doi:  10.1021/acs.biochem.0c00343
[28] AI X Z, WANG S Y, DUAN Y O, et al. Emerging approaches to functionalizing cell membrane-coated nanoparticles[J]. Biochemistry, 2021, 60(13): 941-955. doi:  10.1021/acs.biochem.0c00343
[29] ZHAO Z T, FANG L, XIAO P, et al. Walking dead tumor cells for targeted drug delivery against lung metastasis of triple-negative breast cancer[J]. Adv Mater, 2022, 34(33): e2205462. doi:  10.1002/adma.202205462
[30] BERTI C, GRACIOTTI M, BOARINO A, et al. Polymer nanoparticle-mediated delivery of oxidized tumor lysate-based cancer vaccines[J]. Macromol Biosci, 2022, 22(2): e2100356. doi:  10.1002/mabi.202100356
[31] HAN Q J, WANG Y Q, PANG M, et al. STAT3-blocked whole-cell hepatoma vaccine induces cellular and humoral immune response against HCC[J]. J Exp Clin Cancer Res, 2017, 36(1): 156. doi:  10.1186/s13046-017-0623-0
[32] WANG X L, WANG N, YANG Y, et al. Polydopamine nanoparticles carrying tumor cell lysate as a potential vaccine for colorectal cancer immunotherapy[J]. Biomater Sci, 2019, 7(7): 3062-3075. doi:  10.1039/C9BM00010K
[33] SHI G N, ZHANG C N, XU R, et al. Enhanced antitumor immunity by targeting dendritic cells with tumor cell lysate-loaded chitosan nanoparticles vaccine[J]. Biomaterials, 2017, 113: 191-202. doi:  10.1016/j.biomaterials.2016.10.047
[34] MA L, DIAO L, PENG Z F, et al. Immunotherapy and prevention of cancer by nanovaccines loaded with whole-cell components of tumor tissues or cells[J]. Adv Mater, 2021, 33(43): e2104849. doi:  10.1002/adma.202104849
[35] ROUFARSHBAF M, ESMAEIL N, AKBARI V. Comparison of four methods of colon cancer cell lysates preparation for ex vivo maturation of dendritic cells[J]. Res Pharm Sci, 2021, 17(1): 43-52.
[36] LI X L, ZENG S, HE H P, et al. A hybrid glioma tumor cell lysate immunotherapy vaccine demonstrates good clinical efficacy in the rat model[J]. Onco Targets Ther, 2020, 13: 8109-8124. doi:  10.2147/OTT.S259516
[37] MISHCHENKO T A, TURUBANOVA V D, GORSHKOVA E N, et al. Targeting immunogenic cell death for glioma immunotherapy[J]. Trends Cancer, 2024, 10(1): 8-11. doi:  10.1016/j.trecan.2023.10.005
[38] ZHENG L, DING D, EDIL B H, et al. Vaccine-induced intratumoral lymphoid aggregates correlate with survival following treatment with a neoadjuvant and adjuvant vaccine in patients with resectable pancreatic adenocarcinoma[J]. Clin Cancer Res, 2021, 27(5): 1278-1286. doi:  10.1158/1078-0432.CCR-20-2974
[39] DRANOFF G, JAFFEE E, LAZENBY A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity[J]. Proc Natl Acad Sci U S A, 1993, 90(8): 3539-3543. doi:  10.1073/pnas.90.8.3539
[40] ANDERSON K S, ERICK T K, CHEN M X, et al. The feasibility of using an autologous GM-CSF-secreting breast cancer vaccine to induce immunity in patients with stage II-III and metastatic breast cancers[J]. Breast Cancer Res Treat, 2022, 194(1): 65-78. doi:  10.1007/s10549-022-06562-y
[41] HO V T, KIM H T, BROCK J, et al. GM-CSF secreting leukemia cell vaccination for MDS/AML after allogeneic HSCT: a randomized, double-blinded, phase 2 trial[J]. Blood Adv, 2022, 6(7): 2183-2194. doi:  10.1182/bloodadvances.2021006255
[42] WU A A, BEVER K M, HO W J, et al. A phase II study of allogeneic GM-CSF-transfected pancreatic tumor vaccine(GVAX)with ipilimumab as maintenance treatment for metastatic pancreatic cancer[J]. Clin Cancer Res, 2020, 26(19): 5129-5139. doi:  10.1158/1078-0432.CCR-20-1025
[43] CHUNG D J, SHAH N, WU J, et al. Randomized phase II trial of dendritic cell/myeloma fusion vaccine with lenalidomide maintenance after upfront autologous hematopoietic cell transplantation for multiple myeloma: BMT CTN 1401[J]. Clin Cancer Res, 2023, 29(23): 4784-4796. doi:  10.1158/1078-0432.CCR-23-0235
[44] OGINO H, TAYLOR J W, NEJO T, et al. Randomized trial of neoadjuvant vaccination with tumor-cell lysate induces T cell response in low-grade gliomas[J]. J Clin Invest, 2022, 132(3): e151239. doi:  10.1172/JCI151239
[45] LIAU L M, ASHKAN K, BREM S, et al. Association of autologous tumor lysate-loaded dendritic cell vaccination with extension of survival among patients with newly diagnosed and recurrent glioblastoma: a phase 3 prospective externally controlled cohort trial[J]. JAMA Oncol, 2023, 9(1): 112-121. doi:  10.1001/jamaoncol.2022.5370
[46] BOTA D A, TAYLOR T H, PICCIONI D E, et al. Phase 2 study of AV-GBM-1(a tumor-initiating cell targeted dendritic cell vaccine)in newly diagnosed Glioblastoma patients: safety and efficacy assessment[J]. J Exp Clin Cancer Res, 2022, 41(1): 344. doi:  10.1186/s13046-022-02552-6
[47] CARPENTER E L, VAN DECAR S, ADAMS A M, et al. Prospective, randomized, double-blind phase 2B trial of the TLPO and TLPLDC vaccines to prevent recurrence of resected stage III/IV melanoma: a prespecified 36-month analysis[J]. J Immunother Cancer, 2023, 11(8): e006665. doi:  10.1136/jitc-2023-006665
[48] ADAMS A M, CARPENTER E L, CLIFTON G T, et al. Divergent clinical outcomes in a phase 2B trial of the TLPLDC vaccine in preventing melanoma recurrence and the impact of dendritic cell collection methodology: a randomized clinical trial[J]. Cancer Immunol Immunother, 2023, 72(3): 697-705. doi:  10.1007/s00262-022-03272-8
[49] CHICK R C, FARIES M B, HALE D F, et al. Multi-institutional, prospective, randomized, double-blind, placebo-controlled phase IIb trial of the tumor lysate, particle-loaded, dendritic cell(TLPLDC)vaccine to prevent recurrence in high-risk melanoma patients: a subgroup analysis[J]. Cancer Med, 2021, 10(13): 4302-4311. doi:  10.1002/cam4.3969
[50] VREELAND T J, CLIFTON G T, HALE D F, et al. A phase IIb randomized controlled trial of the TLPLDC vaccine as adjuvant therapy after surgical resection of stage III/IV melanoma: a primary analysis[J]. Ann Surg Oncol, 2021, 28(11): 6126-6137. doi:  10.1245/s10434-021-09709-1
[51] ROCCONI R P, GROSEN E A, GHAMANDE S A, et al. Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial[J]. Lancet Oncol, 2020, 21(12): 1661-1672. doi:  10.1016/S1470-2045(20)30533-7
[52] PODAZA E, CARRI I, ARIS M, et al. Evaluation of T-cell responses against shared melanoma associated antigens and predicted neoantigens in cutaneous melanoma patients treated with the CSF-470 allogeneic cell vaccine plus BCG and GM-CSF[J]. Front Immunol, 2020, 11: 1147. doi:  10.3389/fimmu.2020.01147
[53] CHEN C, WANG Z H, DING Y, et al. Tumor microenvironment-mediated immune evasion in hepatocellular carcinoma[J]. Front Immunol, 2023, 14: 1133308. doi:  10.3389/fimmu.2023.1133308